BRCA1 and breast carcinoma: Despite these very small sample sizes, King et al. concluded a potential reduction in BRCA2 (risk ratio = 0.38; 95% CI 0.06–1.56) but not BRCA1-associated breast cancer (risk ratio = 1.67; 95% CI 0.32–10.7) with tamoxifen use.